Intracellular Concentrations of Posaconazole in Different Compartments of Peripheral Blood

ABSTRACT Therapeutic drug monitoring (TDM) of antifungal plasma concentrations is increasingly recommended. However, data on antifungal concentrations in the other compartments of the peripheral blood are limited. Hence, we collected 23 blood samples from 14 patients receiving posaconazole for prophylaxis of fungal infections. These samples were separated by double-discontinuous Ficoll-Hypaque density gradient centrifugation. The intracellular posaconazole concentrations of the obtained cells, i.e., the peripheral blood mononuclear cells (PBMCs), polymorphonuclear leukocytes (PMNs), and red blood cells (RBCs), were determined by liquid chromatography-tandem mass spectrometry. The intracellular concentrations of the PBMCs and PMNs were significantly higher than those of surrounding media (P < 0.001). The ratios between the intracellular and extracellular concentrations (C/E) were 22.5 ± 21.2, 7.66 ± 6.50, and 0.09 ± 0.05 for the PBMCs, PMNs, and RBCs, respectively. Posaconazole reaches high concentrations within human PBMCs and PMNs and is, to a lesser extent, present in RBCs. The high intracellular concentrations might contribute to posaconazole efficacy and distribution.

[1]  F. Farowski,et al.  Quantitation of Azoles and Echinocandins in Compartments of Peripheral Blood by Liquid Chromatography-Tandem Mass Spectrometry , 2010, Antimicrobial Agents and Chemotherapy.

[2]  M. Rinaldi,et al.  Posaconazole Therapeutic Drug Monitoring: a Reference Laboratory Experience , 2009, Antimicrobial Agents and Chemotherapy.

[3]  J. Perfect,et al.  Posaconazole’s impact on prophylaxis and treatment of invasive fungal infections: an update , 2009, Expert review of anti-infective therapy.

[4]  D. Denning,et al.  Therapeutic drug monitoring for triazoles , 2008, Current opinion in infectious diseases.

[5]  J. Golden,et al.  Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects , 2008, Antimicrobial Agents and Chemotherapy.

[6]  D. Andes,et al.  Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. , 2008, Therapeutic drug monitoring.

[7]  F. Farowski,et al.  Posaconazole: a next-generation triazole antifungal. , 2007, Future microbiology.

[8]  L. Bopp,et al.  Antifungal effect of voriconazole on intracellular Candida glabrata, Candida krusei and Candida parapsilosis in human monocyte-derived macrophages. , 2006, Journal of medical microbiology.

[9]  D. Kontoyiannis,et al.  Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection , 2006, Antimicrobial Agents and Chemotherapy.

[10]  Á. Pascual,et al.  Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. , 2005, The Journal of antimicrobial chemotherapy.

[11]  J. Golden,et al.  Intrapulmonary Pharmacokinetics and Pharmacodynamics of Itraconazole and 14-Hydroxyitraconazole at Steady State , 2004, Antimicrobial Agents and Chemotherapy.

[12]  J. Perfect,et al.  Uptake of itraconazole by alveolar macrophages , 1993, Antimicrobial Agents and Chemotherapy.

[13]  Á. Pascual,et al.  Uptake and intracellular activity of fluconazole in human polymorphonuclear leukocytes , 1993, Antimicrobial Agents and Chemotherapy.

[14]  J. Harlan.  Leukocyte-endothelial interactions. , 1985, Blood.